Idioma:

Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate

Oliveira, J R M ; Oliveira, M F

Scientific reports, 2016-03, Vol.6 (1), p.22961-22961, Article 22961 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate
Autor: Oliveira, J R M ; Oliveira, M F
Assuntos: Adult ; Aged, 80 and over ; Alendronate - therapeutic use ; Alendronic acid ; Basal ganglia ; Bisphosphonates ; Bone Density Conservation Agents - therapeutic use ; Brain - diagnostic imaging ; Brain - drug effects ; Brain - pathology ; Brain Diseases - diagnostic imaging ; Brain Diseases - drug therapy ; Brain Diseases - genetics ; Calcification ; Calcification (ectopic) ; Calcinosis - diagnostic imaging ; Calcinosis - drug therapy ; Calcinosis - genetics ; Case reports ; Central nervous system diseases ; Dementia disorders ; Fatal Outcome ; Female ; Headache ; Heredity ; Humans ; Male ; Middle Aged ; Migraine ; Movement disorders ; Mutation ; Patients ; Proto-Oncogene Proteins c-sis - genetics ; Psychosis ; Side effects ; Studies ; Tomography, X-Ray Computed ; Treatment Outcome
É parte de: Scientific reports, 2016-03, Vol.6 (1), p.22961-22961, Article 22961
Notas: ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Descrição: Brain calcification might be associated with various metabolic, infectious or vascular conditions. Clinically, brain calcification can include symptoms such as migraine, parkinsonism, psychosis or dementia. The term Primary Brain Calcification was recently used for those patients without an obvious cause (formerly idiopathic) while Primary Familial Brain Calcifications was left for the cases with autosomal dominant inheritance. Recent studies found mutations in four genes (SLC20A2, PDGFRB, PDGFB and XPR1). However, these gene represent only 60% of all familial cases suggesting other genes remain to be elucidated. Studies evaluating treatments for such a devastating disease are scattered, usually appearing as single case reports. In the present study, we describe a case series of 7 patients treated with Alendronate, a widely prescribed biphosphanate. We observed good tolerance and evidence of improvements and stability by some patients. No side effects were reported and no specific symptoms related to medication. Younger patients and one individual continuing a prescription (prior to study commencement) appeared to respond more positively with some referred improvements in symptoms. Biphosphanates may represent an excellent prospect for the treatment of brain calcifications due to their being well tolerated and easily available. Conversely, prospective and controlled studies should promptly address weaknesses found in the present analysis.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate

Oliveira, J R M ; Oliveira, M F

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.